Beijing Beilu Pharmaceutical Co., Ltd.

Beijing Beilu Pharmaceutical Co., Ltd. saw a notable increase in stock performance on July 1, 2026, reaching an intraday high. The company reported strong financial results, including a 24.59% growth in operating profit and a 21.7% rise in net sales, reflecting operational efficiency and resilience in the market.

Beijing Beilu Pharmaceutical Co., Ltd. saw a notable increase in stock performance on June 29, 2026, achieving an intraday high. The company reported a significant rise in operating profit and net sales, alongside a record high in operating cash flow, reflecting strong financial health and operational efficiency.

Beijing Beilu Pharmaceutical Co., Ltd. saw a notable increase in stock performance today, contrasting with the broader market. Over the past year, the company achieved a 40.43% return, with net sales growing 21.13% in the first nine months and a half-year net profit of CNY 25.38 million.

Beijing Beilu Pharmaceutical Co., Ltd. saw a notable decline in its stock price today, contrasting with the broader market's performance. Despite recent downturns, the company has shown resilience over the past year, achieving significant stock value growth. Financial metrics indicate steady net sales growth, though long-term outlooks raise concerns.

Beijing Beilu Pharmaceutical Co., Ltd. has seen notable stock performance, with a significant increase on March 6, 2026. The company reported strong financial growth, including a 21.13% rise in net sales and a net profit of CNY 25.38 million for the half-year, reflecting its resilience in the pharmaceuticals sector.

Beijing Beilu Pharmaceutical Co., Ltd. has shown notable stock performance, gaining 6.31% on March 5, 2026, and achieving an intraday high of CNY 10.20. Over the past year, the company has delivered a 51.12% return, with strong net sales and operating cash flow, reflecting solid financial health.